Living Medical Textbook - Hematology - Projects In Knowledge - Insights into Managing Leukemia Table of Contents

Living Medical
Textbook
From Projects In Knowledge

Hematology

Insights into Managing Leukemia

/1921/iPhoneAd/1921iPhoneAd.gif [NO]

Chapter 1
Overview of Leukemia
Release date: October 2009

Chapter 2
Lymphoid Leukemia
Release date: November 2009

Chapter 3
Myeloid Leukemia
Release date: December 2009

Hematology News powered by

Table of Contents

Chapter 1 - Overview of Leukemia
Coming October 2009

Understanding of the molecular biology underpinnings of the leukemias is growing by leaps and bounds and has given rise to new therapies. In this introductory chapter, Dr. Jerald Radich highlights what is known about the relationship between the genetic changes that distinguish the different types of leukemias and the clinical implications of these changes.
top

Chapter 2 - Lymphoid Leukemia
Coming November 2009

Modern treatment strategies for acute lymphocytic leukemia represent a major success story for oncologic research, but success in treatment of chronic lymphocytic leukemia still eludes us. This chapter, edited by Dr. Moshe Talpaz and Dr. Jerald Radich, presents an overview of the state of the art in assessing, treating, and monitoring the lymphocytic leukemias.
top

Chapter 3 - Myeloid Leukemia
Coming December 2009

The overwhelming majority of patients with chronic myeloid leukemia (CML) can now be successfully treated, and complete remissions can be maintained for many years. Patients with acute myeloid leukemia (AML) are not so fortunate, although complete remission can be achieved in more than half of AML patients. This chapter, edited by Neil Shah, MD, PhD, discusses the rationale for treatment approaches now in use for CML and AML.
top

CME INFORMATION

ACTIVITY GOAL

The goals of this CME/CE activity are to:

Increase clinicians’ awareness of the incidence and pathophysiology of leukemia
Apply up-to-date methods for screening and diagnosing patients with leukemia
Utilize up-to-date methods for selecting and assessing treatment interventions that optimize outcomes for patients with leukemia

TARGET AUDIENCE

This activity is designed for hematologists, oncologists, radiation oncologists, family practice/primary care physicians, and other clinicians involved in the management, treatment, and care of patients with leukemia.

LEARNING OBJECTIVES

Apply the most up-to-date knowledge of the etiology, pathophysiology, and diagnosis of leukemia, in order to determine appropriate treatment approaches that maximize patient outcomes.

Assess available methodologies to determine the cytogenetics of different leukemia types, including the Philadelphia chromosome, and their diagnostic and prognostic implications.

Evaluate the appropriate use of current and emerging agents in treatment strategies for patients with leukemia that improve outcomes through knowledge of their mechanism of action, efficacy, and safety.

Utilize emerging data on long-term outcomes in patients with leukemia, in order to monitor health risks and potential cancer recurrence.

top1921

This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation.

EDITORIAL BOARD

EDITOR-IN-CHIEF
Jerald P. Radich, MD

Member
Fred Hutchinson Cancer Research Center
Clinical Research Division
Seattle Cancer Care Alliance
Professor of Medicine
Clinical Research Division
University of Washington School of Medicine
Seattle, Washington

CONTRIBUTING EDITOR
Neil P. Shah, MD, PhD

Assistant Professor Division of Hematology/Oncology UCSF School of Medicine San Francisco, California

CONTRIBUTING EDITOR
Moshe Talpaz, MD

Professor
Department of Internal Medicine—
Hematology/Oncology
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan